Track Nkarta, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Nkarta, Inc. NKTX · Stock Open Nkarta, Inc. in new tab

1.19 USD
EPS
-1.73
P/B
0.49
ROE
-46.58
Beta
1.26
Target Price
10.50 USD
Loading chart...
Key Metrics
Earnings dateMarch 24, 2027
EPS-1.73
Book Value3.01
Price to Book0.49
Debt/Equity33.39
% Insiders4.870%
Estimates
Forward P/E-0.98
Forward EPS-1.51
Target Mean Price10.50

DCF valuation

Model fair value for Nkarta, Inc. (NKTX)
Result
Sign in to run the valuation for NKTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Strong buy · mean target 10.50 USD (low 9.00, high 12.00) · as of 12 Nov 2026
Low 9.00
Mean 10.50
High 12.00
Price 1.19
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Nkarta, Inc. Logo Nkarta, Inc. Analysis (NKTX)

United States Health Care Official Website Stock

Is Nkarta, Inc. a good investment? Nkarta, Inc. (NKTX) is currently trading at 1.19 USD. Market analysts have a consensus price target of 10.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Nkarta, Inc. is expected to release its next earnings report on March 24, 2027. The market consensus estimate for Forward EPS is -1.51.

Investor FAQ

Does Nkarta, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Nkarta, Inc.?

Nkarta, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 24, 2027. The company currently has a trailing EPS of -1.73.

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Exchange Ticker
NMS (United States) NKTX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion